Henry Meds review 2026: the compounded budget play, examined

Henry Meds is the consumer brand of Adonis Health Inc.™ — a cash-pay telehealth platform that connects U.S. patients to licensed clinicians and to compounding pharmacies that prepare individualized prescriptions. The platform itself doesn't deliver clinical care; medical services are provided by an affiliated practice called Colchis Medical Services (also referred to in company materials as Colchis Medical Group), which is the legal entity employing the prescribing physicians and authoring the company's published outcomes paper. This admin-platform / affiliated-medical-practice split is the standard cash-pay-telehealth structure, but Henry foregrounds the "Henry" brand and discloses the underlying entities only in footers and ancillary documents.

The product breadth is narrower than most multi-category telehealth platforms in our set. Henry focuses on four lines: weight management (GLP-1 injectables, oral GLP-1 tablets, phentermine), women's hormone replacement, men's testosterone replacement, and erectile dysfunction. Inside weight management, the GLP-1 line is the headline product — explicitly compounded semaglutide, liraglutide, and tirzepatide, with both injectable and sublingual / orally-dissolving formats available. The company discloses the compounded nature plainly on its product pages: "Compounded medications do not undergo pre-market review or an FDA-approval process. They may differ from commercially available or FDA-approved drugs in efficacy, safety, risk, and side-effect profiles. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications."

The customer-facing information surface is also more sparse than typical for the category. Henry's homepage and product pages do not name the company's founders, do not publish a public physician roster, and do not include the kind of company-stated outcome statistics that several other compounded operators foreground. The named prescribers we could identify surfaced mostly in third-party reviews on Trustpilot — clients name them in passing.

Henry's pricing is unusually well-documented for a compounded provider, but only if you know where to look. The headline product pages display only an entry rate — "starts at $179/month" on the GLP-1 weight management page — and route everything else into the onboarding quiz. The complete price ladder for every program lives on a single document we'll call Henry's Programs page — a legal-footer link most prospective customers will never see. We pulled the following directly from that page on 10 June 2026.

Prices current as of 10 June 2026, taken from Henry Meds's published Programs page (page footer: "Last updated December 3, 2025"). This is a cash-pay market where rates move; we re-verify pricing periodically and update this page when it changes. The most regulation-sensitive line — compounded tirzepatide — we'll recheck after the FDA's 29 June 2026 comment deadline (see section 06).

Henry's longer-term plans carry the same total bill split two ways: paid monthly across the term, or paid in full (PIF) upfront for a meaningful discount. The PIF figures below assume you write a single check at signup for the whole period.

GLP-1 weight management — compounded liraglutide (daily SC injection)

GLP-1 weight management — compounded semaglutide (weekly or biweekly SC injection)

Compounded oral GLP-1 (sublingual or orally-dissolving)

Phentermine

Testosterone replacement (men)

Women's hormone replacement therapy

Erectile dysfunction

The price-anchor problem. Henry's GLP-1 weight management page headlines "starts at $179/month." That number is real, but it's the rate for daily liraglutide, which is the slower, less-effective branded-drug parallel (Saxenda achieved ~8% mean weight loss at 56 weeks in the SCALE trial — see section 04). The more clinically effective weekly semaglutide is $297/month — 66% higher than the hero — and the tirzepatide option (only available orally on Henry's menu) is $1,047 for three months. None of that is hidden once you read the published Programs page, but the headline anchoring is meaningful for a category where most patients want semaglutide or tirzepatide rather than liraglutide.

The multi-month "paid in full" savings are large but front-loaded. Annual semaglutide drops from $3,564 (billed monthly) to $2,364 if you write a $2,364 check at signup — a 34% effective discount and the lowest-priced compounded semaglutide we've found among the providers we cover. The catch is the standard compounded-GLP-1 catch: you're prepaying a year of compounded medication whose availability is regulation-sensitive (see section 06), with a refund mechanic governed by the company's separate Returns & Refunds Policy. The FAQ confirms that mid-term cancellation on a multi-month plan may require paying out the remaining balance unless the discontinuation is medical.

No FSA/HSA acceptance is advertised on the page, and insurance is not accepted. Henry's cash-pay positioning is explicit. There are no Klarna/Affirm/Afterpay options foregrounded on the product surface either, which is unusual at this price point.

No site-wide promo codes are advertised on Henry's own marketing pages. This is structurally different from several competitors in the compounded-DTC category that run visible first-month or auto-applied discount banners. Henry's monthly prices are flat — there is no first-month discount on any monthly plan. The only built-in savings are the paid-in-full multi-month discounts described above. Affiliate-coupon aggregators (RetailMeNot, Wethrift, Coupons.com, and others) list Henry Meds promo codes in the $50 to $150 off range as of June 2026 — codes such as MAMAMEG, WELCOME10, $125 off first month, and "$50 off 1st Month Weight Management" — but validity at checkout varies across aggregators and we have not tested any of them. Innerbody's January 2025 Henry Meds review notes Henry "often provides first-month discounts around most federal holidays in the U.S." Treat affiliate-listed codes as worth checking but not as confirmed.

The funnel is the U.S. cash-pay telehealth template, with one moderately distinctive feature.

Online intake. Click any "Get Started" button on a program page and you're routed to onboard.henrymeds.com to complete a short questionnaire about health, goals, and history. Identity verification is required. The intake adapts based on your answers and gathers more detail where needed.

Provider review. A licensed provider on the Henry / Colchis network reviews the intake. Depending on your state, the visit is either a synchronous video consultation or an asynchronous review of the intake without a video call. Henry doesn't quote a hard turnaround on the medical review step; most cases are completed in under a day based on company copy and customer reports.

Pharmacy and shipping. If approved, the prescription is compounded by a U.S. partner pharmacy. Henry quotes 8–10 business days from provider visit to door, with California specifically called out for longer fulfillment "because of additional compound testing requirements." Reorder cadence is every 45 days for injectables and every 90 days for oral tablets.

Eligibility. For GLP-1 weight management, Henry's published eligibility band is 18 to 70 years old — both a lower and an upper bound, which is more restrictive than most competitors, who simply require 18+ without an upper limit. The clinical reasoning isn't spelled out on the public page, but the practical effect is that patients over 70 will be redirected.

Ongoing care. Unlimited messaging with the care team through the patient portal at app.henrymeds.com; phone support at (909) 787-2342.

Henry's weight-loss outcomes ride on the underlying molecules, not on Henry's care model. The honest question is what compounded semaglutide, tirzepatide, and liraglutide can do — and what's realistic.

The strongest evidence for semaglutide is the STEP 1 trial, which found adults with overweight or obesity lost on average 14.9% of body weight at 68 weeks on once-weekly 2.4 mg semaglutide, versus ~2.4% on placebo, both arms paired with lifestyle support. For tirzepatide, the SURMOUNT-1 trial showed larger average losses — into the ~20%+ range at the higher doses over 72 weeks. For liraglutide, the SCALE Obesity & Prediabetes trial showed daily 3.0 mg achieved ~8% mean weight loss at 56 weeks — meaningfully less than semaglutide, which is consistent with Henry's price structure putting liraglutide as the entry tier.

Three honest caveats belong on this page. First, every one of those trials studied branded, FDA-approved semaglutide, tirzepatide, or liraglutide at defined doses. Henry primarily dispenses compounded versions, which are not the studied products and are not FDA-reviewed for safety or efficacy. The expectation is that the same active molecule behaves similarly, but that's an inference, not trial data. Second, Henry's standard semaglutide protocol titrates to a maximum of about 10–12.5 mg over 70–90 days (per Henry's Programs page, Options 1 and 2) — meaningfully below the doses these trials used, even adjusted for delivery interval. The clinical case for slower titration is reasonable tolerability and adherence, but there isn't a large independent trial base showing that the lower-dose compounded protocol matches full-dose branded weight loss. Third, weight regain after stopping the drug is well-documented; the STEP 1 extension trial found participants regained roughly two-thirds of the weight they had lost within a year of discontinuing semaglutide.

Henry's own marketing claims "On average, people taking injectable Semaglutide with Henry lost ~18% of their body weight in a year," footnoted to a single retrospective cohort published in Journal of Clinical Medical Research in 2025. That paper was authored by Henry / Colchis Medical Services staff (the lead author's correspondence email is at @henrymeds.com), studies Henry's own platform, has no independent control group, and is published in a venue we have not been able to confirm as PubMed-indexed. Under our editorial source-hierarchy standards, a study meeting all four of those conditions is not used as evidence for clinical claims — it's recorded as a fact about Henry's marketing, not as a fact about outcomes. We name the citation here so a reader knows what the company is leaning on; we do not propagate the 18% figure as a documented outcome.

GLP-1 therapy is a well-characterized drug class, and the side-effect profile is consistent across providers. The most common effects are gastrointestinal: nausea, reduced appetite, constipation or diarrhea, and mild digestive discomfort, generally most noticeable when starting or stepping up a dose and often easing with time and dose adjustment. Less common but more serious risks documented for the class include pancreatitis and gallbladder problems. Branded GLP-1s also carry a boxed warning based on rodent studies of thyroid C-cell tumors, and are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2. Pregnancy is a contraindication. Henry's Important Safety Information page lists the common, milder effects; a prescribing provider is supposed to screen for the contraindications at intake, and patients should raise their history directly.

Eligibility for Henry's GLP-1 program is described as age 18 to 70, with the provider exercising clinical discretion on individual approval. The age cap is more restrictive than competitors, which means patients over 70 will need to look elsewhere even if they otherwise meet clinical criteria.

One additional safety consideration is specific to compounded GLP-1 products. Reviews of the FDA's FAERS adverse-event database open data") covering compounded GLP-1 prescriptions (2018–2024) have documented elevated rates of nausea, abdominal pain, gallbladder complications, and hospitalizations relative to branded GLP-1s, alongside potency errors in some compounded sublingual products ranging from 42% to 170% of labeled strength. This is a category-level signal, not a Henry-specific one, but anyone choosing a compounded provider should weigh it.

The single most important context for any compounded-GLP-1 provider in 2026 is the regulatory squeeze. The FDA removed tirzepatide from its shortage list in December 2024 and semaglutide in February 2025; the 503A grace period ended 22 April 2025 and the 503B grace period 22 May 2025. On 30 April 2026 the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List permanently, with public comment open until 29 June 2026. The practical effect is that mass-compounding of these drugs no longer rests on a shortage justification; what remains is narrower, patient-specific compounding. Henry's GLP-1 menu — semaglutide, tirzepatide, and liraglutide — is directly inside the proposed exclusion scope.

Henry's pharmacy classification language is internally consistent across pages. The GLP-1 product page and Trustpilot company-reply text both state medications are "compounded in a 503(A) Compounding Pharmacy or 503(B) Outsourcing Facility" and that the company "exclusively relies on compounded medications from a network of licensed 503(b) and state board of pharmacy licensed 503(a) compounding pharmacies across the US." No internal contradiction across pages. Compounded medications are explicitly disclosed as not FDA-approved.

Active federal lawsuit by Eli Lilly. On April 23, 2025, Eli Lilly and Company filed a federal lawsuit against Adonis Health, Inc. (Henry Meds' parent corporation) in the U.S. District Court for the Northern District of California. According to reporting in NPR, Lilly's complaint against Henry alleges the company "improperly referenced Lilly's approved drugs and clinical trials on its website in order to sell more compounded versions" and specifically calls out Henry's offering of "tirzepatide in pill form, which has never been approved by the FDA." Co-defendants in parallel lawsuits include Mochi Health, Willow Health, Fella Health, and Delilah. On September 24, 2025, a federal judge issued a partial dismissal but allowed Lilly's case against Henry to proceed (per Justia federal court records). The product directly at issue is Henry's compounded oral tirzepatide line — listed at $1,047 for a 3-month supply on Henry's Programs page. The lawsuit is ongoing; outcomes are uncertain; the existence of active manufacturer litigation against the specific product is itself a material consideration for anyone considering signup on that line.

Because availability of compounded tirzepatide specifically is the most regulation-sensitive data point here, we'll recheck it after the 29 June 2026 FDA comment deadline and as the federal lawsuit progresses.

Henry's non-GLP-1 menu is narrower than most multi-category competitors but contains a few distinctive features.

A few observations worth flagging plainly.

The KYZATREX option is FDA-approved branded testosterone — a meaningful credibility signal for Henry's TRT line. Most testosterone-focused DTC providers in our set offer compounded testosterone formats and enclomiphene rather than the FDA-approved oral product, so Henry's inclusion of KYZATREX gives patients a path to a properly-approved oral formulation if they prefer it.

The enclomiphene option inside the $129/mo TRT plan is, in contrast, off-label. Enclomiphene is the trans-isomer of clomiphene citrate (FDA-approved as Clomid for ovulation induction in women, not as a male testosterone therapy). It's prescribed off-label by various providers as a "TRT alternative" because it can raise endogenous testosterone production without exogenous testosterone. Henry's $129 plan lets you pick this option but doesn't foreground its off-label status.

The Programs page does have a couple of copy bugs. Both "Tirzepatide Oral (3-Month Supply)" and "Semaglutide Oral (3-Month Supply)" describe the included medication as "tirzepatide tablets" — the Semaglutide Oral description should say semaglutide. Small editorial slip rather than a substantive issue, but it's the kind of detail a careful patient — and a careful reviewer — notices.

The footer-linked "Medical Weight Loss Bill of Rights" page is, strictly read, a reproduction of Florida Statute 501.0575 rather than a Henry-specific patient-protection commitment. Florida law requires weight-loss providers operating in the state to post that statute; Henry has done so, which is appropriate. The page framing reads as if it's Henry's own initiative, which it is not — it's compliance.

Reading the conflicting third-party signals. Henry presents an unusually split external picture. Trustpilot shows a 4.5-star rating across 12,431 reviews — by sample size and average score, one of the best independent satisfaction signals in our entire compounded-DTC set. The Better Business Bureau rates Henry's parent company (Adonis Health) at F and lists Henry as not BBB-accredited, with documented complaints. These are not the same instrument: Trustpilot captures self-selected user satisfaction at scale and is shaped by which customers the company invites to review, while BBB captures complaints that escalate beyond the company's own resolution process. Both are real signals, and they describe different parts of the experience — most patients are satisfied, a meaningful minority encounter operational issues that reach formal complaint channels. The Pros and Cons below try to keep that honest.

Pros.

Lowest-priced compounded GLP-1 ladder among providers we cover. Annual compounded semaglutide at $2,364 paid in full ($197/mo equivalent) is the lowest annual price we've documented in the compounded category for a high-volume operator.

Substantial Trustpilot footprint. Trustpilot shows 12,431 reviews at 4.5 stars, with the company replying to 100% of negative reviews at a median response time under 24 hours. Henry actively engages with customer feedback at scale.

Active r/henrymeds subreddit. A dedicated patient community discusses experiences with the platform across multiple threads (positive use experiences alongside billing-related concerns). The presence of a sustained patient-facing community is itself a marker of operator scale.

FDA-approved branded TRT option. Including KYZATREX in the TRT menu means patients have access to an FDA-approved oral testosterone formulation, which is uncommon among DTC providers in this category.

Clear, internally consistent 503A/503B disclosure. Henry plainly says compounded medications come from a network of 503(A) and 503(B) pharmacies; the language doesn't contradict itself across pages.

The compounded-medication regulatory caveat is disclosed plainly on every relevant product page in standard language.

Cons and trade-offs.

The hero price anchors on the second-line drug. "$179/month" headlines the GLP-1 page; that's daily liraglutide. The more clinically effective weekly semaglutide is $297/month, and tirzepatide is only offered as a $1,047 / 3-month oral plan. Customers looking for the most-effective option will pay substantially more than the headline.

Multi-month "paid in full" is the value but front-loads risk. The headline annual savings — for example, $2,364 PIF vs $3,564 billed monthly on semaglutide — require committing a year's compounded-medication budget at signup, against a regulatory and litigation backdrop that may change before the year is up (see Cons below on Eli Lilly lawsuit, and section 06).

No public physician roster. Henry does not publish names, credentials, or photos of its prescribing physicians on any product page. From third-party signals — Henry's own "In The News" media coverage, outcomes-paper acknowledgments, and customer reviews on Trustpilot that name clinicians in passing — we identified three Henry-affiliated providers and cross-checked them against the public NPI Registry: one MD (Internal Medicine plus Endocrinology, Diabetes & Metabolism specialty — the right specialty mix for HRT and metabolic care) and two physician assistants (one Utah-based, one California-based). All three are individually registered with current licenses. One additional name surfaced in Trustpilot reviews did not match a clearly Henry-affiliated NPI record at the time of writing. The roster pattern — one MD plus mid-level providers — is consistent with the cost-efficient cash-pay-telehealth model but is materially different from the named-physician transparency you'll find at the larger branded operators.

Headline outcome claim rests on a company-affiliated retrospective. The "~18% weight loss in a year" figure footnotes to a paper authored by Henry / Colchis Medical Services staff, with no independent control group, published in a venue we have not been able to confirm as PubMed-indexed. We don't treat that as evidence.

Billing-related complaints recur in negative reviews. Trustpilot 1-star reviews — 7% of the total, over 800 reviews — frequently cluster on the same themes: unexpected upcharges on multi-month signups, difficulty canceling, auto-renewal disputes, and slow customer-service response on cancellation requests. Several customers have documented resolving billing disputes only after filing a BBB complaint. Henry replies to most of these reviews, but the recurrence is the signal.

BBB rating is F, and Henry is not BBB-accredited. Henry Meds' Better Business Bureau profile lists the parent company as not BBB-accredited with an F rating. Independent third-party reviews documenting this rating include Innerbody's January 2025 review (which observed "12 complaints in the last year") and vaccinealliance.org's May 2026 review. The F rating is consistent with the recurring billing-and-cancellation themes in customer reviews.

Active Eli Lilly federal lawsuit on the oral tirzepatide line. Eli Lilly filed Eli Lilly and Company v. Adonis Health, Inc. in the Northern District of California on April 23, 2025, alleging that Henry "improperly referenced Lilly's approved drugs and clinical trials on its website" and specifically that Henry sells "tirzepatide in pill form, which has never been approved by the FDA." On September 24, 2025, a federal judge granted partial dismissal but allowed Lilly's case to proceed. Henry's oral tirzepatide product ($1,047 / 3-month supply) is directly inside the lawsuit's scope. Outcomes are pending.

Eligibility cap at age 70 is more restrictive than competitors. Patients over 70 will be redirected.

Compounded medications are not FDA-approved, and tirzepatide / semaglutide / liraglutide availability is regulation-sensitive (recheck after the FDA's 29 June 2026 comment deadline).

Henry Meds makes the most sense for the patient who wants a low-priced compounded GLP-1 plan from a high-volume operator and who's willing to prepay a full year for the best per-month equivalent. It fits people who'd rather use the FDA-approved KYZATREX oral testosterone option than a typical compounded TRT format, or who want a single platform that does GLP-1 plus phentermine plus ED plus HRT in one membership-free flow. The Trustpilot sample size is genuinely useful as independent signal: 12,000+ reviews at 4.5 stars from a customer base willing to leave feedback is a more meaningful read than any small-sample peer.

Skip it if you want named-physician transparency before signing up — Henry publishes no roster, and our independent NPI verification produced one MD (Internal Medicine plus Endocrinology specialty) and two physician assistants (Utah and California) from third-party sources, not from Henry's own pages. Skip it if a hassle-free refund mechanic matters — the Trustpilot complaint pattern around cancellation and refunds, combined with the BBB F rating, warrants close review of the multi-month terms before paying upfront. Skip it if you're 70 or older — Henry's age cap excludes you from GLP-1 care here. Skip it if you specifically want oral tirzepatide and want to avoid a product line under active manufacturer litigation — the Eli Lilly federal lawsuit is ongoing and specifically targets that product. And skip it if you're hoping for the best-evidence drug regimen at the headline price — the "$179/month" hero is for liraglutide, not semaglutide or tirzepatide.

Our editorial position is to keep head-to-head verdicts in dedicated comparison pages rather than inside any single review. The shape of Henry's position in the landscape, though, is clear enough to summarize at the level a reader needs.

Against the broad multi-category compounded providers (TeleZenMD, Mochi Health), Henry has a narrower menu but lower entry pricing and a substantially larger Trustpilot footprint. Against the public, branded-only operators (Hims, Ro), Henry's price floor is much lower, but the evidence base for compounded products is weaker than for the branded FDA-approved drugs those companies dispense. Against the men's-hormone-focused category (Maximus), Henry's TRT line includes an FDA-approved oral option (KYZATREX) that Maximus doesn't, but Maximus has a more credentialed urology advisory board and publishes its named physicians by name.

The clearest case for Henry over any of those alternatives is wanting the lowest-priced compounded GLP-1 from an operator with real customer volume — knowing the trade-offs around the unpublished roster, the company-affiliated outcomes paper, and the billing-complaint pattern.

How we reviewed this. Pricing, programs, and process details were pulled directly from Henry Meds's public pages — the homepage, GLP-1 weight management page, Programs page (the company's full price ladder), FAQ, Values page, Bill of Rights, In The News, and Important Safety Information page — in June 2026. The Programs page was the primary source for pricing; the page footer states "Last updated December 3, 2025." Prescriber verification was conducted independently against the public NPI Registry: three Henry-affiliated clinicians identified through third-party sources (Henry's "In The News" media coverage, outcomes-paper acknowledgments, and Trustpilot customer reviews) were cross-checked. Result: one MD with Internal Medicine plus Endocrinology, Diabetes & Metabolism taxonomy, and two physician assistants (Utah and California). All three are individually registered with current licenses. Third-party review platforms: Trustpilot shows 4.5 stars across 12,431 reviews with a 7% one-star share — a meaningful sample. Better Business Bureau lists Henry's parent (Adonis Health) as not BBB-accredited with an F rating, corroborated by Innerbody's January 2025 review and vaccinealliance.org (May 2026). A dedicated r/henrymeds subreddit exists with active customer discussion. Federal litigation history: Eli Lilly and Company v. Adonis Health, Inc. filed April 23, 2025 in the U.S. District Court for the Northern District of California; partial dismissal on September 24, 2025 but case allowed to proceed. Primary source: NPR coverage and Justia federal docket. We do not publish invented customer experiences. Clinical claims in this review are anchored to peer-reviewed primary trials (STEP 1, STEP 1 extension, SCALE, SURMOUNT-1) and FDA primary sources; we do not propagate the "~18% weight loss" figure Henry markets, which rests on a company-affiliated self-published retrospective and does not clear our editorial evidence bar.

Editorial independence. PeptideWellness does not accept payment from telehealth providers, compounding pharmacies, or manufacturers in exchange for coverage, placement, or scoring. We have no commercial relationship with Henry Meds or Adonis Health Inc.

Editorial note: Informational only — not medical advice. Compounded medications aren't FDA-approved and don't undergo the same safety, effectiveness, or manufacturing review as branded pharmaceuticals. GLP-1 and peptide therapy decisions should be made with a licensed healthcare provider familiar with your medical history. Last reviewed June 2026.